5 Undervalued Biotechnology & Medical Research Stocks for Thursday, October 26
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Thursday, October 26 based on AAII’s Stock Grades.Grace Malone
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Commentary & Analysis
4 Undervalued Biotechnology & Medical Research Stocks for Tuesday, August 01
Discover the top 4 undervalued Biotechnology & Medical Research stocks for Tuesday, August 01 based on AAII’s Stock Grades.Eunice Kim
Is Chemomab Therapeutics Ltd - ADR (CMMB) Stock a Good Investment?
Learn more about Chemomab Therapeutics Ltd - ADR's (CMMB) stock grades for Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | CMMB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $18.7 | $269.3 | 9% |
|
| Shares Out (Mil) | 8.0 | 54.0 | 18% |
|
| Institutional Ownership | 52.6% | 93.0% | 36% |
|
| Float (Mil) | 6.1 | 42.2 | 14% |
|
| Beta | 0.66 | 0.95 | 39% |
|
| Avg Daily Volume (000s) | 83 | 473 | 34% |
|
| Price Change (52-week) |
(13.7%) | 55.9% | 37% |
|
| Growth | CMMB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (8.4%) | (10.1%) | 30% |
|
| EPS (5yr) | 16.5% | 15.7% | 61 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 21.9% | (15.6%) | 81% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | $0.000 | ($0.020) | ($0.030) | |
| Month Ago EPS | $0.000 | ($0.020) | ($0.030) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $0.000 | ($0.020) | ($0.030) | |
| Year/Year Chg | (100.0%) | (98.6%) | (97.2%) | |
| Financials | CMMB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($8) | ($43) | 31% |
|
| EPS (TTM) | ($1.007) | ($1.500) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($31) | 21% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $9 | $182 | 7% |
|
| Valuation | CMMB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.15 | 2.62 | 54% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CMMB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (73.5%) | na |
|
| ROA | (61.0%) | (47.9%) | 10% |
|
| ROE | (80.9%) | (55.0%) | 11% |
|
| Liabilities to Assets | 15.2% | 29.5% | 9% |
|
| F-Score | 3 | 3 | 18% |
|
Chemomab Therapeutics Ltd. did not pass any screens on 9/11/2026.
